Competitive Technologies, Inc.'s Calmare(R) Chronic Pain Therapy Device in KSL-TV News Report Entitled "FDA-Approved Device Offers Non-Drug Option for Pain"

FAIRFIELD, Conn., June 12, 2013 (GLOBE NEWSWIRE) -- Competitive Technologies, Inc. (OTCQX:CTTC), the licensed distributor of the non-invasive Calmare® chronic pain therapy medical device, announced today that the company's non-invasive and non-narcotic chronic pain therapy technology was highlighted in a recent KSL-TV News report. The news segment highlighted the experience of patients who were successfully treated for their chronic pain with the Calmare medical device, developed by Professor Giuseppe Marineo.

The news report video is accessible at:

The patients interviewed in the news report had been suffering with Reflex Sympathetic Dystrophy (RSD), Idiopathic Neuropathy, Neurovascular Dystrophy and severe hip pain and had tried various therapies, including narcotic painkillers.

Scrambler Therapy is extremely effective in treating a significant percentage of patients who are unresponsive or minimally responsive to painkillers – including those based on opiates – or other forms of pain treatment such as conventional electroanalgesia.

Calmare has been receiving more attention in the medical community as more clinical studies are being conducted. As more physicians utilize Calmare treatments with their chronic pain patients, more patient testimonials, including those highlighted in the TV report, are being recognized.

About Competitive Technologies, Inc.

Competitive Technologies is a global leader in developing and commercializing innovative products and technologies. CTTC is multifaceted, providing distribution, patent and technology transfer, sales and licensing services.

CTTC is the licensed distributor of the non-invasive Calmare® pain therapy medical device, which incorporates the biophysical Scrambler Therapy® system developed in Italy by CTTC's client, Professor Giuseppe Marineo to treat neuropathic pain, including cancer pain. (The official Scrambler Therapy® scientific and clinical information website is at For more information on the device, visit Visit CTTC's website:

Statements made about our future expectations are forward-looking statements and subject to risks and uncertainties as described in our most recent Annual Report on Form 10-K for the year ended December 31, 2012, filed with the SEC on May 31, 2013, and other filings with the SEC, and are subject to change at any time. Our actual results could differ materially from these forward-looking statements. We undertake no obligation to update publicly any forward-looking statement.

CONTACT: Direct inquiries to: Jean Wilczynski, IR Services, LLC (860.434.2465 / info@corpirservices.comSource:Competitive Technologies, Inc.